Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera

Jenny J Wei; Lisa R Kallenbach; Maryl Kreider; Thomas H Leung; Misha Rosenbach

doi:10.1016/j.jdcr.2019.02.006

Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera

JAAD Case Rep. 2019 Apr 5;5(4):360-361. doi: 10.1016/j.jdcr.2019.02.006. eCollection 2019 Apr.

Authors

Jenny J Wei¹, Lisa R Kallenbach², Maryl Kreider³, Thomas H Leung^{1

4}, Misha Rosenbach¹

Affiliations

¹ University of Pennsylvania Perelman School of Medicine, Department of Dermatology, Philadelphia, Pennsylvania.
² University of Pennsylvania Presbyterian Medical Center, Department of Hematology Oncology, Philadelphia, Pennsylvania.
³ University of Pennsylvania, Department of Pulmonary, Allergy & Critical Care, Philadelphia, Pennsylvania.
⁴ Corporal Michael Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania.

No abstract available

Keywords: JAK inhibitor; JAK, Janus kinase; JAK-STAT, Janus kinase–signal transducer and activator of transcription; Janus kinase inhibitor; Janus kinase–signal transducer and activator of transcription; PV, polycythemia vera; ruxolitinib; sarcoidosis.

Publication types

Case Reports